Dharma Biologics

Every Program Rests on Its Drug Substance

Before there is a formulation.
Before there is a vial, a syringe, or a device.
Before regulators, inspections, or supply chains.

There is drug substance.

Drug substance defines the biological identity, manufacturability, and long-term viability of a therapeutic program. Decisions made at this stage echo forward—sometimes for years.

Dharma Biologics treats drug substance not as an upstream task, but as the structural foundation of the entire product lifecycle.

As a high quality CDMO in India, we design drug substance programs to support not just early success, but durable scale, regulatory confidence, and commercial reliability.

Why Drug Substance Is Where Order Matters Most

Drug substance development is where complexity first appears.

Expression systems behave unpredictably.
Impurities emerge subtly.
Small process changes produce outsized effects.

Many failures attributed to downstream manufacturing originate here—at the molecular and process level.

Dharma Biologics approaches drug substance with a systems mindset:

• we design for control, not just yield
• we prioritize reproducibility over optimization theater
• we align development with eventual manufacturing reality

This is how we operate as a biologics CDMO in India trusted with high-value, high-scrutiny programs.

An Integrated Drug Substance Philosophy

At Dharma Biologics, drug substance development, scale-up, and cGMP manufacturing exist within a single conceptual framework.

This integration allows us to:

• preserve process knowledge across phases
• avoid rework during tech transfer
• reduce regulatory risk caused by late-stage changes

Drug substance work at Dharma is never isolated. It is continuously informed by downstream needs—drug product, device integration, and regulatory strategy.

This continuity is one of the defining traits of a premium CDMO in Asia.

Microbial and Mammalian Systems — Chosen with Intent

Dharma Biologics supports both microbial and mammalian expression systems, selected based on scientific fit, scalability, and regulatory context.

We do not force molecules into platforms.
We choose platforms that respect molecules.

Our teams work closely with sponsors to evaluate:

• expression efficiency
• impurity profiles
• scalability constraints
• long-term commercial feasibility

This disciplined selection process prevents many downstream challenges before they arise.

Process Development as Risk Management

Process development is often framed as optimization.

At Dharma Biologics, it is framed as risk management.

We focus on:

• understanding process sensitivity
• identifying critical parameters early
• designing processes that tolerate variation

This approach produces processes that scale predictably and perform consistently.

As a high quality CDMO in India, we believe a slightly lower yield with higher robustness is often the smarter choice.

Cell Line and Strain Engineering: Precision at the Source

The quality of drug substance is inseparable from the quality of the cell line or strain that produces it.

Dharma Biologics applies disciplined engineering principles to:

• cell line development
• strain optimization
• clone selection

We evaluate candidates not only for productivity, but for:

• stability over time
• scalability
• regulatory acceptability

This upstream rigor simplifies everything that follows.

Analytical Insight Drives Substance Control

Drug substance programs succeed or fail based on how well they are understood.

Dharma Biologics integrates analytical development tightly with process development, enabling:

• early impurity identification
• informed process decisions
• smoother comparability exercises

Analytics at Dharma do not merely report outcomes.
They guide execution.

This integration is essential for any biologics CDMO in Asia supporting regulated-market programs.

Scale-Up Without Reinvention

One of the most common pain points sponsors experience is scale-up that feels like starting over.

Dharma Biologics avoids this by designing development work with scale in mind from the outset.

Our scale-up philosophy emphasizes:

• preserving process intent
• minimizing parameter drift
• maintaining documentation continuity

As programs move from development to pilot and commercial scale, the system remains coherent.

This is how order protects momentum.

cGMP Drug Substance Manufacturing: Built for Trust

Dharma Biologics offers cGMP drug substance manufacturing designed to support:

• clinical supply
• commercial launch
• long-term lifecycle management

Our manufacturing systems emphasize:

• process control
• batch-to-batch consistency
• data integrity
• regulatory transparency

As a cGMP biologics CDMO in India, we design operations so that audits validate decisions already made—rather than expose weaknesses.

Regulatory Alignment from the First Experiment

Drug substance decisions are regulatory decisions, whether acknowledged or not.

Dharma Biologics integrates regulatory thinking into drug substance work by:

• aligning analytical strategies with filing requirements
• documenting development rationale clearly
• designing processes that regulators can understand and trust

This proactive alignment reduces late-stage questions and accelerates approvals.

Drug Substance Within the CDMO Network

Through the CDMO Network, Dharma Biologics extends drug substance capabilities while maintaining consistency.

Network alignment enables:

• standardized tech transfer
• shared best practices
• redundancy without fragmentation

Sponsors benefit from flexibility without sacrificing control—a critical advantage for global programs.

India’s Strength in Substance, Refined

India’s pharmaceutical ecosystem brings deep experience in fermentation, biologics processing, and regulated manufacturing.

Dharma Biologics refines this strength by:

• eliminating legacy shortcuts
• institutionalizing best practices
• designing systems for future regulatory expectations

As a high quality CDMO in India, we build on what India does best—then raise the bar.

Drug Substance as a Strategic Choice

Choosing a drug substance partner is one of the most consequential decisions a sponsor makes.

It determines:

• manufacturing success
• regulatory trajectory
• long-term supply security

Dharma Biologics approaches this responsibility with seriousness and restraint.

We do not overpromise.
We design systems that hold.

Drug Substance, Summarized

At Dharma Biologics, drug substance work is defined by:

• systems thinking
• disciplined development
• scalable processes
• regulatory alignment
• continuity across phases

This approach allows us to function as one of the most trusted biologics CDMOs in India and Asia for complex, high-value programs.

Order Is the Source. Substance Is the Foundation.

ಅಡಿಪಾಯದಲ್ಲಿ ಶಕ್ತಿ. ಅಣುವಿನಲ್ಲಿ ನಿಯಂತ್ರಣ.